Search for                  In:
	Alltitlebodyauthorsinstitutionsdatetimesession
andornot	Alltitlebodyauthorsinstitutionsdatetimesession
andornot	Alltitlebodyauthorsinstitutionsdatetimesession

Show results 10203040 at a time.

Your search has been listed in order of relevancy

Click the checkbox next to each item to bookmark.
	1.	[2035] Transcriptional profiling of patient-matched ER-positive breast cancer tissue from post-menopausal women treated with neoadjuvant RAD001.
		Authors: Sabine VS, Sims AH, Macaskill EJ, Renshaw L, Thomas JS, Dixon JM, Bartlett JMS
		Date/Time: Friday, December 12, 2008 - 7:00 AM
		Session Info: Poster Session II: Tumor Cell and Molecular Biology: Molecular Profiles (7:00 AM-9:00 AM)
	2.	[4063] Mutation of PI3KCA in post-menopausal women with breast cancer and response to RAD001 treatment.
		Authors: Sabine VS, Ferguson J, Thelwell N, Macaskill EJ, Renshaw L, Whitcombe D, Thomas JS, Dixon JM, Bartlett JMS
		Date/Time: Saturday, December 13, 2008 - 7:00 AM
		Session Info: Poster Session IV: Tumor Cell and Molecular Biology: Oncogenes / Tumor Suppressor Genes (7:00 AM-9:00 AM)
	3.	[406] Multicenter phase I clinical trial of daily and weekly RAD001 (everolimus) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab.
		Authors: Fasolo A, Gianni L, Rorive A, Bergh J, Dieras V, Cardoso F, Vittori L, Pylvaenaeinen I, Sahmoud T, Jerusalem G
		Date/Time: Friday, December 12, 2008 - 7:00 AM
		Session Info: Poster Discussion Session: Novel Targeted Therapies (7:00 AM-9:00 AM)
	4.	[2032] Predicting response to RAD001 treatment in post-menopausal women with ER-positive breast cancer using the breast cancer DSA research tool (Almac).
		Authors: Sabine VS, McCulla A, Wilson CL, Sims AH, McDyer F, McCluskey C, Halfpenny I, Oliver GR, Macaskill EJ, Renshaw L, Thomas JS, Dixon JM, Bartlett JMS
		Date/Time: Friday, December 12, 2008 - 7:00 AM
		Session Info: Poster Session II: Tumor Cell and Molecular Biology: Molecular Profiles (7:00 AM-9:00 AM)
	5.	[3119] RAD001 (everolimus) in combination with weekly paclitaxel and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab: a multicenter phase I clinical trial.
		Authors: O'Regan R, Andre F, Campone M, Naughton M, Manlius C, Pylvaenaeinen I, Sahmoud T, Hurvitz S
		Date/Time: Friday, December 12, 2008 - 5:00 PM
		Session Info: Poster Session III: Treatment: Advanced Therapy - Targeted (5:00 PM-7:00 PM)
	6.	[405] Combination of carboplatin and the mTor inhibitor RAD001 is a new therapeutic approach for p53-mutated breast cancer.
		Authors: Liu H, Possinger K, Eucker J
		Date/Time: Friday, December 12, 2008 - 7:00 AM
		Session Info: Poster Discussion Session: Novel Targeted Therapies (7:00 AM-9:00 AM)